Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Vaccines

PUBLISHER: TechSci Research | PRODUCT CODE: 1732869

Cover Image

PUBLISHER: TechSci Research | PRODUCT CODE: 1732869

Human DNA Vaccine Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Route of Administration, By Application, By End User, By Region & Competition, 2020-2030F

PUBLISHED:
PAGES: 180 Pages
DELIVERY TIME: 2-3 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4500
PDF and Excel (Multi-User License)
USD 5500
PDF and Excel (Custom Research License)
USD 8000

Add to Cart

We offer 8 hour analyst time for an additional research. Please contact us for the details.

Description

Table of Contents

The Global Human DNA Vaccine Market was valued at USD 345.44 million in 2024 and is projected to reach USD 523.99 million by 2030, growing at a CAGR of 7.15%. This market is undergoing robust growth fueled by advancements in genetic engineering, increased investment in the healthcare sector, and heightened demand for cutting-edge therapeutic and preventive solutions. DNA vaccines operate through the direct delivery of engineered plasmid DNA encoding specific antigens, stimulating precise immune responses. These vaccines stand out for their enhanced safety profile, shorter development timelines, and adaptability across a broad spectrum of diseases. Positioned within the dynamic vaccine industry, the DNA vaccine market is poised for rapid evolution driven by continuous technological breakthroughs, expanded clinical applications, and heightened global health priorities. Companies that align with regulatory trends and innovate in delivery technologies are expected to gain significant competitive advantages.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 345.44 Million
Market Size 2030USD 523.99 Million
CAGR 2025-20307.15%
Fastest Growing SegmentIntramuscular
Largest MarketNorth America

Key Market Drivers

Rising Prevalence of Infectious and Chronic Diseases

The escalating occurrence of both infectious and chronic diseases is a critical driver for the Global Human DNA Vaccine Market. In 2021, approximately 18 million people died prematurely from noncommunicable diseases (NCDs), with 82% of these deaths occurring in low- and middle-income countries (LMICs), underscoring the disproportionate impact on economically disadvantaged regions. Furthermore, LMICs accounted for 73% of all NCD-related deaths globally. This significant health burden amplifies the need for innovative vaccination approaches like DNA vaccines, which are gaining momentum due to their unique benefits. Notably, in 2023, about 1.3 million people contracted HIV worldwide, a 39% reduction in new cases from 2010, indicating a global infection rate of 0.17 per 1,000 uninfected individuals. As diseases such as HIV, Hepatitis, Tuberculosis, HPV, COVID-19, Zika, and Ebola continue to challenge public health systems, DNA vaccines offer scalable, adaptable, and long-lasting immune protection-traits that are increasingly in demand globally.

Key Market Challenges

Limited Clinical Success and Regulatory Approvals

Despite encouraging outcomes in preclinical stages, human DNA vaccines face challenges in achieving strong clinical efficacy. A primary obstacle is their lower immunogenicity in humans when compared to traditional vaccine types, which often leads to suboptimal immune responses in clinical settings-especially when conventional administration methods are used. Consequently, regulatory approval for human use remains limited, with most authorizations to date focused on veterinary applications. Although the pandemic has accelerated interest in DNA vaccines for humans, regulatory bodies continue to require comprehensive data on long-term safety and efficacy. These stringent and often uncertain regulatory demands present a substantial hurdle, particularly for smaller biotech firms, thereby slowing commercial progress and investment in the field.

Key Market Trends

Shift Toward Platform-Based Vaccine Technologies

The vaccine sector is witnessing a strong trend toward platform-based technologies, which leverage a unified system for developing multiple vaccines. DNA vaccine platforms exemplify this model. By standardizing delivery mechanisms, production processes, and clinical trial protocols, these platforms significantly cut down on development time and costs. They also enable rapid responses to emergent health threats, supporting quicker vaccine rollouts. Pharmaceutical companies and investors are increasingly attracted to this scalable framework, which not only fosters efficient product pipelines but also strengthens pandemic preparedness strategies. These systems support diverse disease applications, enhance public-private collaborations, and draw funding from global health stakeholders.

Key Market Players

  • BOEHRINGER INGELHEIM GmbH (Merial)
  • ELI-LILLY (Novartis Animal Health)
  • Gene One Life Science
  • GEOVAX LABS, INC
  • Inovio Pharmaceuticals (VGX Animal Health)
  • Genexine, Inc.
  • VIATRIS INC. (Rottapharm Biotech)
  • Takara Holdings (Takara Bio)
  • ZOETIS INC. (Fort dodge Animal Health)
  • Zydus Lifesciences Limited

Report Scope:

In this report, the Global Human DNA Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Human DNA Vaccine Market, By Route of Administration:

  • Intramuscular
  • Subcutaneous
  • Intradermal
  • Others

Human DNA Vaccine Market, By Application:

  • Oncology
  • Tuberculosis
  • HIV
  • Others

Human DNA Vaccine Market, By End User:

  • Hospitals & Clinics
  • Biotechnology & Pharmaceutical Companies
  • Academic & Research Institutions
  • Others

Human DNA Vaccine Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Human DNA Vaccine Market.

Available Customizations:

Global Human DNA Vaccine market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Show more
Product Code: 14276

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Human DNA Vaccine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others)
    • 5.2.2. By Application (Oncology, Tuberculosis, HIV, Others)
    • 5.2.3. By End User (Hospitals & Clinics, Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Human DNA Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Route of Administration
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Human DNA Vaccine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Route of Administration
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Human DNA Vaccine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Route of Administration
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Human DNA Vaccine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Route of Administration
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Human DNA Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Route of Administration
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Human DNA Vaccine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Route of Administration
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. United Kingdom Human DNA Vaccine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Route of Administration
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. Italy Human DNA Vaccine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Route of Administration
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. France Human DNA Vaccine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Route of Administration
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Human DNA Vaccine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Route of Administration
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia-Pacific Human DNA Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Route of Administration
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Human DNA Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Route of Administration
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Human DNA Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Route of Administration
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Human DNA Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Route of Administration
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Human DNA Vaccine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Route of Administration
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Human DNA Vaccine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Route of Administration
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. South America Human DNA Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Route of Administration
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Human DNA Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Route of Administration
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Human DNA Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Route of Administration
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Human DNA Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Route of Administration
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. Middle East and Africa Human DNA Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Route of Administration
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Human DNA Vaccine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Route of Administration
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Human DNA Vaccine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Route of Administration
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Human DNA Vaccine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Route of Administration
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Human DNA Vaccine Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. BOEHRINGER INGELHEIM GmbH (Merial)
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. ELI-LILLY (Novartis Animal Health)
  • 14.3. Gene One Life Science
  • 14.4. GEOVAX LABS, INC
  • 14.5. Inovio Pharmaceuticals (VGX Animal Health)
  • 14.6. Genexine, Inc.
  • 14.7. VIATRIS INC. (Rottapharm Biotech)
  • 14.8. Takara Holdings (Takara Bio)
  • 14.9. ZOETIS INC. (Fort dodge Animal Health)
  • 14.10.Zydus Lifesciences Limited

15. Strategic Recommendations

16. About Us & Disclaimer

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!